Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts

BMC Cardiovascular Disorders
Henock G YebyoMilo A Puhan

Abstract

Patient preferences are key parameters to evaluate benefit-harm balance of statins for primary prevention but they are not readily available to guideline developers and decision makers. Our study aimed to elicit patient preferences for benefit and harm outcomes related to use of statins for primary cardiovascular disease prevention and to examine how the preferences differ across economically and socio-culturally different environments. We conducted preference-eliciting surveys using best-worst scaling designed with a balanced incomplete-block design (BIBD) on 13 statins-related outcomes on 220 people in Ethiopia and Switzerland. The participants made tradeoff decisions and selected the most and least worrisome outcomes concurrently from each scenario generated using the BIBD. The design yielded 34,320 implied paired-comparisons and 2860 paired-responses as unit of analysis for eliciting the preferences that were analyzed using a conditional-logit model on a relative scale and surface under the cumulative ranking curve from multivariate random-effects meta-analysis model on a scale of 0 to 1. There was high internal consistency of responses and minimal amount of measurement error in both surveys. Severe stroke was the most worr...Continue Reading

References

Jan 15, 1998·Social Science & Medicine·P F KrabbeG J Bonsel
Nov 5, 1999·Journal of the National Cancer Institute·M H GailV Vogel
Nov 27, 1999·BMJ : British Medical Journal·T Arnesen, E Nord
Nov 23, 2007·Nature·Abdallah S DaarJohn Bell
Feb 5, 2008·Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention·J A HaagsmaG J Bonsel
Mar 21, 2009·Health Economics·Daniel M Hausman
Jan 10, 2012·Population Health Metrics·Kyle J ForemanChristopher Jl Murray
Nov 21, 2012·BMC Medical Research Methodology·Milo A PuhanCynthia M Boyd
Jun 5, 2013·European Journal of Preventive Cardiology·Hugo Saner
Aug 21, 2013·Health Research Policy and Systems·Hyacinthe Tchewonpi KankeuDavid B Evans
Oct 30, 2013·JAMA : the Journal of the American Medical Association·Victor M MontoriM Hassan Murad
May 6, 2014·Journal of Clinical Lipidology·Robert S Rosenson The National Lipid Association's Muscle Safety Expert Panel
Jun 18, 2014·Journal of Travel Medicine·Silja BühlerVeronika K Jaeger
Jan 19, 2016·Population Health Metrics·Juanita A HaagsmaJoshua A Salomon
Jul 13, 2016·PharmacoEconomics·Kei Long CheungMickael Hiligsmann
Oct 27, 2016·JAMA : the Journal of the American Medical Association·Kirsten Bibbins-Domingo
Nov 14, 2016·JAMA : the Journal of the American Medical Association·Roger ChouThomas L Jeanne
Jan 4, 2018·Annals of Internal Medicine·Martin Bødtker Mortensen, Børge Grønne Nordestgaard

❮ Previous
Next ❯

Citations

Jul 2, 2019·Annals of Internal Medicine·Paul C Sorum
Jul 2, 2019·Annals of Internal Medicine·Henock G YebyoMilo A Puhan
Sep 6, 2020·Multiple Sclerosis and Related Disorders·Alessandra SpanuMilo A Puhan
Mar 16, 2021·JAMA Network Open·Suzanne BrodneyMichael J Barry

❮ Previous
Next ❯

Software Mentioned

STATA
SAS
R

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.